Oncotarget

Research Papers:

MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Yang Lin, Tianmin Xu, Shunqing Zhou and Manhua Cui _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101649-101658. https://doi.org/10.18632/oncotarget.21417

Metrics: PDF 801 views  |   HTML 1237 views  |   ?  


Abstract

Yang Lin1, Tianmin Xu1, Shunqing Zhou1 and Manhua Cui1

1Department of Obstetrics and Gynecology, The Second Hospital, Jilin University, Nanguan District, Changchun 130041, China

Correspondence to:

Manhua Cui, email: cuimanhua1326@163.com

Keywords: microRNAs; miR-363; ovarian cancer; NOB1

Received: May 11, 2017     Accepted: September 04, 2017     Published: September 30, 2017

ABSTRACT

In this study, we investigated the role of microRNA-363(miR-363) in ovarian cancer (OC) progression. MiR-363expression was downregulated in OC patient tissues and four OC cell lines (SKOV3, A2780, OVCAR and HO-8910). Low miR-363 levels were associated with advanced stage, lymph node metastasis, and poor prognosis in OC. MiR-363 overexpression decreased growth, colony formation, migration and invasiveness of SKOV3 cells. In addition, miR-363 overexpression in SKOV3 cells also decreased xenograft tumor size and weight in nude mice. Bioinformatics and dual luciferase reporter assays revealed that miR-363 suppresses expression of NIN1/RPN12 binding protein 1 homolog (NOB1) by binding to the 3’-UTR of its transcript. NOB1 expression inversely correlated with miR-363 levels in OC tissues. Thus miR-363 appears to play a tumor suppressor role in OC by inhibiting NOB1.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21417